Background: Adverse drug events (ADEs) are identified as a major cause of morbidity and place a significant burden on patient safety and health-care resources. Previous studies have examined hospital admissions associated with ADEs but involved limitations including retrospective design and nongeneralizable results. Research Question: What are the predictors of hospital admissions associated with both preventable and nonpreventable ADEs in the general population? Methods: This was a prospective observational study that took place in the medical admission units of two National Health Service hospitals, one community (A) and one teaching (B), in the UK.
Of the 439 admissions for a causal ADE, 207 (47.6 %) were preventable and 230 (52.4 %) were non-preventable ADEs. Preventable ADEs were more common in patients who were ≥65 years old, had three or more coexisting conditions, or were prescribed five or more medications.
The drug groups most commonly associated with preventable ADEs were those used for cardiovascular (61 %), CNS (14 %), and endocrine disorders (12 %). Antiplatelet medications (11 %) and oral anticoagulants (9 %) were the two most common drug classes involved in preventable ADEs. Conclusion: Preventable ADEs occurred more frequently in patients ≥ 65 years of age, with three or more coexisting medical conditions, or taking five or more medications. Non-preventable ADEs were move common in patients <65 years of age. Hospital site (community rather than a teaching facility) was a risk factor for ADEs. For the first time, the length of time since starting a new prescription drug was shown to predict admission for an ADE. Critique: The criteria used to determine if admissions were related to ADEs were vast and subjective. A team of three reviewers was used to classify admissions and ADEs; disagreements were settled via discussion. A more appropriate method may have involved individual reviews and reporting measures of inter-rater variability. The inclusion of intentional ingestions (which could be considered non-ADEs) and not actively collecting data on weekends (convenience sampling) are other limitations. Lastly, the data suggested that patients admitted to a community hospital were significantly more likely to have a causal ADE. However, there was no discussion of the possible reasons for this finding. Implication for Toxicologists: Better understanding of the risks associated with ADEs may help with the development of prescribing protocols or warnings for specific drugs in certain populations. Identifying a novel variable (i.e., the time since starting a new prescription medication) as a risk factor for preventable ADEs may introduce preventive medicine roles that poison centers can play such as providing follow-up calls to patients given new prescriptions.
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Background : Poisoning with organophosphorous compounds (OPCs) is a frequent cause of human morbidity with increased concerns due to their potential use as chemical warfare agents (i.e. sarin and tabun). Since OPCs are potent inhibitors of acetylcholinesterase (AChE), they cause an increased amount of acetylcholine in synapses, excessive stimulation of nicotinic and muscarinic receptors with resultant effects.
The current therapeutic strategy for OPC poisoning includes atropine to block muscarinic receptor stimulation and oximes to regenerate AChE activity. However, these post-exposure treatments have many limitations. Animal studies suggest that better therapeutic results are achieved when non-organophosphate AChE inhibitors are given prior to OPC exposure. The theory behind this effect is that non-OPC inhibitors form an unstable bond with AChE that temporarily occupies its catalytic site and protects the enzyme from phosphorylation by the OPC. Research Question: What are the efficacies of ten different non-OPC AChE inhibitors when given prior to paraoxon in reducing paraoxon-induced mortality? Methods : The non-OPC AChE inhibitors tested were pyridostigmine, physostigmine, ranitidine, tiapride, tacrine, 7-methoxytacrine, amiloride, K-27, metoclopramide and methylene blue. The study was performed on Wistar rats and involved 11 study groups. One group of rats received paraoxon alone. The other ten groups were each pretreated with one of the non-OPC AChE and then received paraoxon. Each of the ten treatment groups was subdivided into three arms, each received a different intraperitoneal dose of paraoxon (1, 2 or 3 μmol). Each test subject received 25 % of the LD 01 for each non-OPC AChE inhibitor via intraperitoneal injection 30 min prior to receiving paraoxon. A control group of 60 rats (receiving only one of each of the non-OPC AChE inhibitors) was also used. Animals that received paraoxon alone (but no pretreatment) were regarded as the reference group (RR=1). The animals were monitored for 48 h, and mortality was recorded at set time intervals. Results: Survival of the experimental animals was dependent on both the non-OPC AChE used for pretreatment and the dose of paraoxon. All rats in the control group (non-OPC AChE inhibitor only) survived. The non-OPC AChEs with the most protection from paraoxon-induced mortality were physostigmine (RR = 0.30 ± 0.15) and K-27 (RR = 0.34 ± 0.09). Metoclopramide-(RR=1.28 ±0.18), amiloride-(RR= 1.27±0.18) and methylene blue-(RR=1.27±0.19) treated animals had increased mortality. All other non-OPC AChE inhibitors provided modest protection. Conclusion : This study suggested that the best preexposure protection by non-OPC AChE inhibitors from paraoxon mortality was with physostigmine and K-27. Some non-OPC AChE inhibitors (metoclopramide, amiloride and methylene blue) increased mortality.
Critique: Although various non-OCP AChE inhibitors were examined, only one OPC was used to induce mortality. Related data suggest that OPCs interact differently with different test medications. Of the non-OPC AChE inhibitors studied, many (n =5) confidence intervals crossed 1.0, suggesting no effect on mortality. Using mortality as an endpoint overlooks other OPC effects, such as profuse gastroenteritis and depressed mental status, which could lead to mortality in an uncontrolled environment. Lastly, the limitations of studying pre-exposure interventions were not discussed. Implication for Toxicologists: Finding an effective prophylactic measure for OPC poisoning is crucial in providing safety for many patient populations and the military. Certain non-OPC AChE inhibitors are widely available and may prevent the depletion of atropine in a mass poisoning situation. The presented data suggest that further work on the prevention of OPC toxicity is needed. Methods: This was a retrospective case review of 26 impaired driving cases in the state of Washington. The authors reviewed drug recognition expert officer reports of each incident, field sobriety test results and toxicology studies. A blood butalbital concentration was recorded in each case. Other drug and ethanol concentrations were also determined. Two specific cases were presented in detail to illustrate findings. Results: Twenty-one of the 26 (81 %) cases involved female drivers and 19 (73 %) were between 30 and 50 years of age. The median butalbital concentration was 16 mg/L (range, 1.0-30.2 mg/L). Documented signs of driving impaired included erratic lane travel, striking parked vehicles and driving into oncoming traffic. Performance on field sobriety testing was more impaired as butalbital concentration increased. Vertical gaze nystagmus was seen in 12 of 19 drivers (63 %) with butalbital concentrations above the reported therapeutic range.
Conclusion: Elevated blood butalbital concentrations are associated with progressively impaired driving in a concentrationdependent manner. A significant number of impaired drivers had blood butalbital concentrations above the therapeutic range. The authors concluded that butalbital should be tested for in cases of impaired driving where CNS depressant use is suggested.
Critique: This review furthers the description of butalbital's ability to impair driving. It is interesting to note that many drivers had butalbital concentrations above the therapeutic range. However, it is difficult to conclude that butalbital alone was responsible for the impaired driving noted in each case. Other drugs, at low concentrations, were found in some samples. The contribution of these or other unidentified substances on the subjects' driving is unknown. Also, it would be helpful to know how each subject was using butalbital (i.e. as directed or not). Implication for Toxicologists : The association between butalbital and impaired driving is documented. Checking a butalbital concentration may be helpful in forensic cases of impaired driving, especially if the scenario suggests use of a CNS depressant. Background: Rattlesnake envenomation is accompanied by hematologic dysfunction, specifically hypofibrinogenemia and thrombocytopenia. In the USA, antivenom treatment involves the use of Crotalidae Polyvalent Ovine Immune Fab (CroFab®), a Fab antivenom. Latin American countries treat similar envenomations with a F(ab′) 2 preparation [Anavip®; Antivenin Crotalinae (Pit Viper) Equine Immune F(ab′) 2 ]. F(ab′) 2 is currently not approved for use in the USA. Differences in pharmacokinetics and renal clearance between the two products suggest that F(ab′) 2 will stay in circulation longer than Fab, which may result in different hematologic effects. Research Question: Will longer plasma persistence of F(ab′) 2 antivenom, relative to Fab, in patients at risk for coagulopathy result in decreased venonemia and coagulopathy 1 week after treatment? Methods: This was a clinical trial comparing Fab and F(ab′) 2 in the treatment of adults bitten by rattlesnakes in Tucson, Arizona. Subjects were randomized to receive either Fab or F(ab′) 2 as an initial dose and then as three maintenance doses, each given 6 h apart. Additional "stabilizing" and maintenance doses were permitted at "physician discretion." Blood was routinely drawn throughout the procedure and during a 2-week follow-up period. Quantitative levels of venom, antivenom, fibrinogen and platelets were measured from available samples. All adverse events were recorded from the initiation of antivenom therapy through follow-up day 21. Results: A total of 12 patients were enrolled; six subjects received each antivenom. Both the Fab and F(ab′) 2 were equally effective in reducing initial free venom concentrations in subjects as well as leading to a recovery of platelet and fibrinogen levels. Baseline plasma venom levels before treatment in the Fab and F(ab′) 2 groups were 489±501 ng/ml (range, 79-1202) and 369±424 ng/ml (range, 0.01-1134), respectively. After the prescribed maintenance doses, both groups had venom levels that measured 0.01±0.0 ng/ml (below detection). Plasma antivenom levels were significantly higher in the F(ab′) 2 group compared to the Fab group after maintenance dosing (1,207±391 mcg/ml (range, 702-1,652) versus 255±109 mcg/ml (range, 107-383)), respectively. At follow-up, patients who received F(ab′) 2 had a platelet nadir that was significantly higher than those who received Fab: 214 ± 58 k/mm 3 (range, 127-280) compared with 87 ± 43 k/mm 3 (range, 26-135), respectively. Finally, the fibrinogen nadir was nonsignificantly higher in the F(ab′) 2 group when compared with the Fab group: 275±70 mg/dl (range, 170-390) compared to 164±94 mg/dl (range, 19-274) . Four of six patients treated with Fab had detectable venom levels after their maintenance doses were given. None of the patients given F(ab′) 2 ever had a subsequent rise in venom levels during follow-up. One patient in the Fab group was rehospitalised for thrombocytopenia below 50 k/mm 3 and one had a protracted hospital course due to thrombocytopenia below 50 k/mm 3 ; both received further antivenom. No study participants developed serious reactions to either antivenom. Conclusion : Rattlesnake envenomation is associated with acute and delayed effects including thrombocytopenia and hypofibrinogenemia. The use of F(ab′) 2 compared to Fab resulted in decreased late hypofibrinogenemia and thrombocytopenia, less recurrent venonemia and persistent antivenom levels.
Critique: This paper showed that using F(ab′) 2 antivenom may have a more favorable hematologic outcome when compared to Fab antivenom. However, the methods involved an unblinded study, small sample sizes and a treatment protocol that enabled physicians to vary treatment. A larger, blinded study with strict treatment protocol is required. Furthermore, the baseline demographics between the patients in the Fab and F(ab′) 2 groups were different and it is unclear if this affected the results. Finally, it would be helpful to know how the different treatment protocols studied affected local envenomation effects such as tissue necrosis and edema. Implication for Toxicologists: Toxicologists should be cognizant that subacute coagulopathy may develop in patients treated with antivenom for rattlesnake envenomations. F(ab′) 2 appears to be superior to Fab based on limited data and current dosing regimens. Optimal dosing strategies and follow-up period are yet to be determined.
